Related Experiment Video
Updated: Jan 14, 2026
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
Published on: November 18, 2022
Immediate Postoperative AbnobaVISCUM® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic
Seung Soo Hong1,2, Munseok Choi1,3, Seoung Yoon Rho1,3
1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Purpose:
AbnobaVISCUM® F is an anti-malignant tumor agent derived from Viscum album, a mistletoe species parasitic to ash trees. It is known to exert anticancer effects by activating the patient's immune system without directly inducing tumor toxicity. We retrospectively investigated the anticancer effect of AbnobaVISCUM® F in patients with resected pancreatic cancer.
Materials And Methods:
We reviewed a total of 985 patients who underwent radical resection for pancreatic cancer between January 2005 and August 2022 at Severance Hospital, Seoul, Korea. Patients were divided into two groups based on whether Abnoba VISCUM® F was administered (Viscum group) or not (Control group), and clinicopathologic characteristics, disease-free survival (DFS) and overall survival (OS) were compared after propensity score matching (PSM).
Results:
Of the 985 patients, 310 received Viscum therapy at least 12 times (Viscum group), while 590 did not receive it at all (Control group). After PSM, both groups showed similar DFS (p=0.518), whereas the Viscum group showed superior OS (p<0.001). Subgroup analyses revealed better OS for the Viscum group in T1 (p=0.014), T2 (p=0.012), N0 (p=0.010), N1 (p=0.001), R0 resection patients (p<0.001), and in patients who underwent no adjuvant chemotherapy or chemotherapy regimens other than FOLFIRINOX (p<0.001). Multivariable analysis identified Viscum therapy as an independent factor for improved OS (hazard ratio 0.601, p< 0.001), although it did not significantly impact DFS.
Conclusion:
Viscum treatment significantly improved OS in patients with completely resected stage I and II pancreatic cancer, particularly among those unable to tolerate adjuvant chemotherapy. This anticancer effect, based on immune enhancement, should be further investigated, and large-scale randomized controlled study is warranted.
More Related Videos
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
08:12Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:30Acute Pancreatitis II: Clinical Manifestations and Management